Warning: This data is provided for information purpose only. You should not start or stop any medication without consulting your care giver.
Use the Health Monitor application at http://www.healthsupportsystems.com to search for a drug by brand, generic or symptom
ABILIFY
Active Ingredients
ARIPIPRAZOLE
Inctive Ingredients
cornstarch,hydroxypropyl cellulose,lactose monohydrate,magnesium stearate,microcrystalline cellulose,ferric oxide (yellow or red),FD&C Blue No. 2 Aluminum Lake
Usage
ABILIFY is indicated for the treatment of schizophrenia. The efficacy of ABILIFY in the treatment of schizophrenia was established in short-term (4- and 6-week) controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY: Clinical Studies).
The efficacy of ABILIFY in maintaining stability in patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer, were discontinued from those other medications, and were then administered ABILIFY 15 mg/day and observed for relapse during a period of up to 26 weeks was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Studies). The physician who elects to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).